UK Markets closed

Sanofi (GCVRZ)

NASDAQ Global Market - NASDAQ Global Market Real-time price. Currency in USD
Add to watchlist
0.383+0.013 (+3.514%)
As of 1:17PM EDT. Market open.
People also watch
CELGZGALTWWMGIZCYHHZPRPH
  • E
    Elizabeth
    Elizabeth
    Is SNY overvalued at current levels? This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awe.som_sto-cks is the one i like best.
  • J
    Jason
    Jason

    Interesting read on drug pricing strategy...

    http://www.biopharmadive.com/news/drug-pricing-recipe-launch-price-sanofi/449004/

    The secret recipe behind the launch price of a drug
    Finding the right ingredients to set the perfect drug price is a little bit of art and a whole lot of science.
    www.biopharmadive.com
  • A
    Ashley
    Ashley
    SNY, looks to be overvalued at this price Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awe-som_sto-cks.
  • T
    Taylor
    Taylor
    If we are to go off the RSI then you could argue that a pull back next day or so could occur on SNY before rallying up. Ive been struggling with this stock lately. Some of my other trades have been from awesome*sto-cks which are working out pretty well.
  • M
    Morgan
    Morgan
    Downside risk pretty much eliminated now I would guess, thoughts? Im not sure about you guys but Awe.Some.Sto-ck.s has provided me with some pretty good trade ideas. I messed up executing some of them but thats on me.
  • H
    Hannah
    Hannah
    Downside risk pretty much eliminated now I would guess, thoughts? google awe*some*sto-ck*s - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • M
    Mia
    Mia
    Is SNY undervalued? This sort of setup suggests potential upside... This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awe*some*sto-ck*s is the one i like best.
  • P
    Paige
    Paige
    SNY has just seen the last of the selling. Looks like a potential push higher is in store. I started receiving notifications from awesome_stocks the other week and so far they have presented interesting new trade ideas.
  • O
    Oclrmet
    Oclrmet
    Its strength in its profitability and solvency. Both rated "A" at stockFA.
  • A
    Amy
    Amy

    Received an alert this am about $GCVRZ from http://jcharlesassets.com/opiant-pharmaceuticals/?s=GCVRZ, you may want to take a look. "rht" Investing day trading.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • M
    MicroC
    MicroC
    Why would someone use multiple usernames to post nonsense?
  • n
    neil
    neil
    SNY cranking up new highs!
  • A
    Anonymous
    Anonymous
    SNY has up 20% in last two months, not bad. But need more clear path for growth of revenue.
  • A
    AF
    AF
    SNY should be up today. FDA approved. What is happening? Any idea?
  • B
    Bob
    Bob
    serious unbiased question? why the strong gain last few months ( even adj for annual dividend)? new trial drug? takeover target? acquisition? Something driving
  • n
    nito
    nito

    MYMETICS (MYMX) got the goodies for this too!!!

    https://finance.yahoo.com/news/could-better-way-protect-against-194902205.html

    There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold
    Flu vaccines need to be administered annually. Sanofi's research team thinks they can...
    finance.yahoo.com
  • B
    Bio
    Bio
    Charles A. Henriques ( Global Popularity, A Bright Star In Pharma) Linkedin.com
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain
    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area: Linkedin 1799 Linkedin.com Connections

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. $1.9 Billion, sales worldwide.
  • D
    Dan
    Dan

    Received an alert this am about $GCVRZ from http://thesubwaytrader.com/?s=GCVRZ, you may want to take a look. Making money investing. John's collateral corollary: in order to get a loan you must first prove you don't need it.

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
    thesubwaytrader.com
  • T
    Tom
    Tom
    Just saw this : Sanofi First Quarter Profit Rises Driven by Performance in Specialty HealthCare Division, Consumer Products

    BY Midnight Trader
    — 11:26 AM ET 04/28/2017
    Business net income totaled 1.80 billion euros ($1.97 billion), or 1.42 euros per share, compared with 1.72 billion euros, or 1.34 euros per share, in the same quarter a year earlier, results published by company on Friday showed. Net sales increased 11.1% to 8.65 billion euros, lifted by the acquisition of Boehringer Ingelheim's consumer healthcare business and full consolidation of Sanofi's European vaccine unit. At constant business structure and currencies, sales rose 3.5%, the company said.

    Genzyme sales increased 15.5% at constant currencies driven by multiple sclerosis products, while sales were down 7.7% at constant currencies at the diabetes and cardiovascular business, dragged down by lower demand for the company's diabetes products in the US, including Lantus for type-2 diabetes.

    Sales at the vaccines unit jumped 13.2% at constant structure and currencies led by children's products and at the consumer health care business they were 4.7% higher on the same basis.
    Stock goes up a whole 13 cents!!!!!!!!!!!!!!!
  • n
    neil
    neil

    MYMETICS Corp. (MYMX)---under-the-radar sleeping gem

    http://www.mymetics.com/

    Home
    Mymetics Corp. is an international biotechnology company successfully focused on developing virosome based vaccines to combat human infectious diseases.
    www.mymetics.com
Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more